Healthcare / BiotechnologyNasdaqGS
$4.14
-0.02 (-0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-80.0M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$263M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-134.2%
↓Gross Margin
75.9%
↑Debt/Equity
0.66
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
—
FCF margin
-55.5%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $149.5M · net income $-74.6M · FCF $-83.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $149.5M | $149.5M | $150.0M | $58.7M | $150.0M | $77.4M | $104.9M | $64.2M | $60.1M | $157.7M | $91.9M | $100.9M | $47.8M | $58.0M | $63.8M | $57.2M |
| Net Income | $-74.6M | $-74.6M | $-67.0M | $-9.1M | $-119.8M | $-202.1M | $-129.7M | $-151.8M | $-171.5M | $-19.6M | $-58.5M | $-20.1M | $-38.3M | $-261000.00 | $8.4M | $6.7M |
| EBITDA | $-59.6M | $-59.6M | $-57.4M | $2.0M | $-107.9M | $-191.5M | $-119.1M | $-164.9M | $-162.0M | $-14.9M | $-52.4M | $-17.3M | $-36.5M | $1.6M | $9.2M | $6.3M |
| EPS | — | — | -1.07 | -0.15 | -1.95 | -3.37 | -2.47 | — | — | — | — | — | -1.40 | -0.04 | 0.00 | 0.00 |
| Gross Margin | 75.9% | 75.9% | 91.8% | 86.0% | 95.1% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -48.7% | -48.7% | -73.7% | -286.4% | -80.9% | -261.9% | -125.0% | -276.0% | -284.8% | -14.0% | -65.3% | -20.0% | -80.2% | 0.6% | 12.9% | 9.2% |
| Net Margin | -49.9% | -49.9% | -44.7% | -15.4% | -79.8% | -261.0% | -123.7% | -236.5% | -285.2% | -12.4% | -63.7% | -20.0% | -80.2% | -0.4% | 13.1% | 11.7% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.66 | 0.66 | 0.32 | 0.22 | 0.25 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.90 | 1.90 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-83.0M | $-83.0M | $-72.1M | $-80.0M | $-90.6M | $-150.0M | $-117.8M | $-138.6M | $-178.2M | $-15.0M | — | — | — | $-17.1M | $-7.5M | $6.3M |
| Returns | ||||||||||||||||
| ROE | -134.2% | -134.2% | -57.7% | -5.9% | -84.3% | -84.3% | -43.8% | -65.8% | -70.6% | -6.6% | -21.8% | -6.4% | -31.6% | -0.3% | -101.5% | -38.4% |
| Valuation | ||||||||||||||||
| EV/EBITDA | — | — | — | 266.76 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 4.72 | 4.72 | 1.87 | 3.96 | 2.47 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -0.3% | -0.3% | 155.3% | -60.8% | — | -26.2% | 63.4% | 6.8% | -61.9% | 71.7% | -8.9% | 111.0% | -17.6% | -9.1% | 11.6% | — |
| EPS Growth | — | — | -613.3% | 92.3% | — | -36.4% | — | — | — | — | — | — | -3400.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+204.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.07 → n/d
Residual
+204.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.